

Cyclacel Pharmaceuticals, Inc.  
Form 8-K  
September 16, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): September 16, 2008**

**CYCLACEL PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction  
of incorporation)**

**0-50626  
(Commission File Number)**

**91-1707622  
(IRS Employer  
Identification No.)**

**200 Connell Drive  
Suite 1500  
Berkeley Heights, NJ 07922  
(Address of principal executive offices and zip code)  
Registrant's telephone number, including area code: (908) 517-7330**

**(Former Name or Former Address, if Changed Since Last Report)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):**

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EX-99.1: PRESS RELEASE

---

**Table of Contents**

**Item 8.01 Other Events.**

On September 16, 2008, Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the Company ), issued a press release announcing a revision of its operating plan. A copy of the press release is furnished as Exhibit 99.1 hereto.

The Company will conduct a conference call to review this announcement on Tuesday, September 16, 2008, at 4:30 p.m., Eastern Time.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Number	Description
99.1	Press release, dated September 16, 2008

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By: /s/ Paul McBarron

Name:

Paul McBarron

Title: Executive Vice President Finance and  
Chief Operating Officer

Date: September 16, 2008

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
<b>99.1</b>	Press Release, dated September 16, 2008